Africa CDC chief has pledged to deploy a vaccine developed for a previous Ebola strain to address the ongoing outbreak in the Democratic Republic of Congo. The announcement followed release of data from test cases that, according to the agency, indicate the vaccine may afford a level of protection that could reduce mortality and transmission in the current situation. The head of the Africa Centres for Disease Control described the move as an emergency public health measure based on the available evidence.
The vaccine in question was originally formulated against an earlier Ebola virus strain; the agency said that limited test-case evaluations show signals of cross-protection against the virus circulating in the DRC. Details provided by the Africa Centres for Disease Control did not include the full scope of the tests or comprehensive clinical trial results, and the agency emphasized that ongoing evaluation will be required to confirm the extent of protection in broader use.
The pledge sets in motion plans for targeted deployment of the vaccine in affected areas, with the explicit aim of interrupting transmission chains and protecting high-risk populations. The agency indicated that logistics for storage and distribution will be arranged to meet cold-chain requirements and to reach frontline health workers and contacts of confirmed cases. The decision reflects a balance between the immediacy of the outbreak and the current experimental evidence from the cited test cases.
Health authorities and observers will continue to follow the situation closely, with the Africa Centres for Disease Control reporting updates as additional data on safety and effectiveness emerge. The agency stressed the importance of rigorous monitoring and data collection during deployment to inform future use of the vaccine and to guide public health actions in the region.
